April 24, 2014

As part of the launch of DSN’s new microsite, DrugStoreNews.com/Pain-Management, DSN had the opportunity to speak with Carmen Catizone, executive director of the National Association of Boards of Pharmacy, regarding a new initiative that the association is spearheading to address the current patient access problem when it comes to pain management pharmaceuticals.

January 23, 2014

In a recent report, 59News explored how DEA regulations on pain medications can limit a pharmacy's supply, preventing patients from obtaining their medications.

January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

January 2, 2014

One reason pain patient advocates are so passionate about what they do is because they are pain patients themselves — they know the stigma associated with chronic pain; they know how difficult it can be to access appropriate pain therapy sometimes. That’s the story of Gina Libby, volunteer pain patient advocate who has lived with chronic pain for more than 20 years.

October 27, 2014

Prestige Brands on Monday reiterated that it is expanding its partnership between Goody's and NASCAR driver Dale Earnhardt Jr.

October 23, 2014

Preliminary results of an open-label trial carried Thursday in the journal of Headache and Pain reported that a single treatment with ElectroCore’s hand held non-invasive vagus nerve stimulation device GammaCore, completely resolved 44.8% of migraines within 30 minutes.

October 21, 2014

Over-the-counter painkillers and anti-inflammatory drugs may also be effective in the treatment of people suffering from depression.

 

October 15, 2014

The resurgence of iconic pain relief brands Tylenol and Excedrin continue to contribute to the slight growth across internal analgesic tablets. It’s a $3.2 billion book of business across U.S. multi-outlets, according to IRI, that is up slightly by 0.8% for the 52 weeks ended Aug. 10. 

September 15, 2014

Bayer HealthCare on Monday launched Aleve PM, the first over-the-counter nighttime product with a safe sleep aid plus the 12-hour pain-relieving strength of Aleve.

September 10, 2014

SpiderTech recently announced the launch of its pre-cut kinesiology tape that provides drug-free relief for anyone suffering from minor aches and pain.

September 5, 2014

Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.

August 27, 2014

Low-dose aspirin lowers the occurrence of new venous blood clots — and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in Monday's issue of Circulation.

August 22, 2014

The Drug Enforcement Administration issued a final rule rescheduling hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act.

August 20, 2014

Wahl is differentiating itself from other products on the shelf through a new approach that combines a massager with hot-cold gel packs, helping to increase circulation and reduce swelling.

August 20, 2014

The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.

August 20, 2014

Excedrin relaunched in the United States in 2013 and is doing well. The brand generated $130 million between its Excedrin tablets and Excedrin Migraine tablets for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.

August 20, 2014

Who is the alternative analgesic pain consumer? “The majority of these people [in search of external pain relief] have chronic pain and are already taking prescriptions and using multiple methods of pain relief,” said Jenny McLaughlin, product manager for Walh Therapeutic Massagers. “Our research shows people are coming into the health-and-wellness area once a month.”

August 20, 2014

Perfecta Products last year added Zim’s Arnica Max to it’s lineup of external analgesic rubs, which includes Zim’s Max-Freeze, an $11.8 million brand grew 27.3% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.

August 20, 2014

The entire external analgesic category is up 6.7%, reaching a base of $486.9 million across total U.S. multi-outlets for the 52 weeks ended June 15, according to IRI data. And Salonpas, with a 10.9% dollar share, is helping to drive that growth with positive sales gains of 28.7% to $52.9 million.

August 20, 2014

Researchers at the University of California, San Diego School of Medicine concluded that aspirin, in addition to preventing pain and inflammation, actually helps hasten the end of inflammation in a study published this week in the online early edition of PNAS.

August 20, 2014

GM Pharmaceuticals recently launched 8-oz. bottles of its liquid pain reliever, VanaPain, which includes 16 servings of its daytime pain reliever and eight servings of its nighttime pain reliever.

August 12, 2014

According to a survey conducted by Mom Central in partnership with McNeil Consumer Healthcare, many moms feel ill-equipped to manage the discomfort that comes along with many childhood "firsts." 

August 1, 2014

PuraMed BioScience on Wednesday announced that the company is rebranding the LipiGesic M name along with the name's red and yellow logo, to be replaced with the trademarked name MigraPure  going forward.

July 17, 2014

Purdue Pharma announced that the Food and Drug Administration approved a new 7.5-mcg/hour dosage strength of Butrans (buprenorphine) transdermal system CIII.